F. E. Von Eyben Et Al. , "177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer," Oncotarget , vol.10, no.25, pp.2451-2461, 2019
Von Eyben, F. E. Et Al. 2019. 177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer. Oncotarget , vol.10, no.25 , 2451-2461.
Von Eyben, F. E., Singh, A., Zhang, J., Nipsch, K., Meyrick, D., Lenzo, N., ... Kairemo, K.(2019). 177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer. Oncotarget , vol.10, no.25, 2451-2461.
Von Eyben, Finn Et Al. "177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer," Oncotarget , vol.10, no.25, 2451-2461, 2019
Von Eyben, Finn E. Et Al. "177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer." Oncotarget , vol.10, no.25, pp.2451-2461, 2019
Von Eyben, F. E. Et Al. (2019) . "177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer." Oncotarget , vol.10, no.25, pp.2451-2461.
@article{article, author={Finn Edler Von Eyben Et Al. }, title={177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer}, journal={Oncotarget}, year=2019, pages={2451-2461} }